Innate Pharma SA (IPH) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Vétoquinol SA

OSE Immunotherapeutics SA

Ipsen SA

Sanofi

DBV Technologies SA

Genfit SA

Sensorion SA

Cellectis SA

MedinCell SA

Innate Pharma SA

PHAXIAM Therapeutics SA

Why is Innate Pharma SA ?

Poor long term growth as Operating profit has grown by an annual rate 0.09% of over the last 5 years

Flat results in Jun 25

ROCE(HY) Lowest at -271.38%
NET SALES(Q) Lowest at EUR 1.67 MM
OPERATING PROFIT MARGIN(Q) Lowest at -1,670.2 %

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -41.36%, its profits have fallen by -30.2%

Consistent Underperformance against the benchmark over the last 3 years

Along with generating -41.36% returns in the last 1 year, the stock has also underperformed France CAC 40 in each of the last 3 annual periods

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Innate Pharma SA for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Innate Pharma SA

-100.0%

-1.64

49.93%

France CAC 40

0.34%

-0.10

17.53%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-33.81%

EBIT Growth (5y)

0.09%

EBIT to Interest (avg)

-39.43

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-5.65

Sales to Capital Employed (avg)

0.33

Tax Ratio

13.15%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

23.19

EV to EBIT

-1.50

EV to EBITDA

-1.54

EV to Capital Employed

-3.08

EV to Sales

14.35

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-914.21%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bullish

Dow Theory

Mildly Bearish

No Trend

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

5What is working for the Company

NET PROFIT(HY)

Higher at EUR -21.81 MM

DEBT-EQUITY RATIO (HY)

Lowest at -641.49 %

RAW MATERIAL COST(Y)

Fallen by 0% (YoY

-9What is not working for the Company

ROCE(HY)

Lowest at -271.38%

NET SALES(Q)

Lowest at EUR 1.67 MM

OPERATING PROFIT MARGIN(Q)

Lowest at -1,670.2 %

CASH AND EQV(HY)

Lowest at EUR 60.03 MM

Here's what is working for Innate Pharma SA

Net Profit

Higher at EUR -21.81 MM

than preceding 12 month period ended Jun 2025

MOJO Watch

In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (EUR MM)

Debt-Equity Ratio

Lowest at -641.49 % and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Raw Material Cost

Fallen by 0% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Innate Pharma SA

Net Sales

Lowest at EUR 1.67 MM and Fallen

In each period in the last five periods

MOJO Watch

Near term sales trend is very negative

Net Sales (EUR MM)

Net Sales

At EUR 1.67 MM has Fallen at -79.85%

Year on Year (YoY)

MOJO Watch

Near term sales trend is very negative

Net Sales (EUR MM)

Operating Profit Margin

Lowest at -1,670.2 % and Fallen

In each period in the last five periods

MOJO Watch

Company's profit margin has deteriorated

Operating Profit to Sales

Cash and Eqv

Lowest at EUR 60.03 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents